Recent Transactions

02-May-18
$3.7 billion
Canada flag
Target: 

Concordia International Corp.

flag not available

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

27-Mar-18
$13.0 billion
Switzerland flag
Target: 

Novartis AG’s 36.5% stake in Consumer Health Joint Venture

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

09-Jan-18
$3.1 billion
Canada flag
Target: 

Pure Industrial Real Estate Trust

United States flag
Acquiror: 
Blackstone Property Partners

Advised the Special Committee of the Board of Trustees of Pure Industrial Real Estate Trust ("PIRET"), the largest pure-play industrial REIT in Canada, regarding the acquisition of PIRET by Blackstone Property Partners

22-Dec-17
$5.3 billion
United Kingdom flag
Target: 

Ladbrokes Coral Group PLC

United Kingdom flag
Acquiror: 
GVC Holdings PLC

Advised Ladbrokes Coral Group PLC, a leading multi-channel sports betting and gaming company, on a recommended offer from GVC Holdings PLC, a multi-national online sports betting and gaming company

30-Nov-17
$NA
Spain flag
Target: 

Grupo Sidecu

Spain flag
Acquiror: 
Portobello Capital

Advised the shareholders of Grupo Sidecu, the leading concessional sport center operator in Spain, on its sale of a controlling stake to Portobello Capital, a local private equity fund

30-Nov-17
$NA
Germany flag
Target: 

MorphoSys AG

China flag
Acquiror: 
I-Mab

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

31-Oct-17
$2.0 billion
South Africa, Switzerland flags
Target: 

Hirslanden Private Hospital Group

flag not available

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

06-Oct-17
$18.4 billion
United States flag
Target: 

Caesars Entertainment

flag not available

Advised selected Second Lien Noteholders, including Canyon Capital Advisors, Mason Capital, Paulson & Co. and Soros Fund Management regarding Caesars Entertainment Operating Company’s Chapter 11 proceedings

18-Jul-17
$NA
Brazil flag
Target: 

Radiogroup Participações S.A.

Brazil flag
Acquiror: 
Grupo Oncoclínicas

Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas

11-May-17
$245 million
Saudi Arabia Flag
Target: 

Equity stake in Bupa Arabia

United Kingdom flag
Acquiror: 
Bupa Ltd.

Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia

20-Apr-17
$4.3 billion
Canada flag
Target: 

Brookfield Canada Office Properties

United States flag
Acquiror: 
Brookfield Property Partners L.P.

Advised the Special Committee of Brookfield Canada Office Properties, Canada’s pre-eminent office real estate investment trust, on its go private transaction with Brookfield Property Partners L.P.

10-Jan-17
$204 million
United States flag
Target: 

Derma Sciences, Inc.

United States flag
Acquiror: 
Integra LifeSciences Holdings Corporation

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on its sale to Integra LifeSciences Holdings Corporation, a global leader in medical technology

09-Jan-17
$465 million
United States flag
Target: 

Palatin Technologies, Inc. lead product candidate, Rekynda

United States flag
Acquiror: 
AMAG Pharmaceuticals, Inc.

Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.

24-Nov-16
$NA
Israel flag
Target: 

Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.

Switzerland flag
Acquiror: 
Rivopharm SA

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA

23-Nov-16
$NA
Israel flag
Target: 

Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.

France flag
Acquiror: 
Arrow Generiques SAS

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

13-Oct-16
$NA
U.S.A., Canada flags
Target: 

Concordia International Corp

flag not available

Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process

05-Oct-16
$775 million
U.K., Ireland flags
Target: 

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m) 

05-Oct-16
$NA
Israel flag
Target: 

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

04-Oct-16
$223 million
U.S.A., U.K. flags
Target: 

U.S. rights to Toprol-XL (AstraZeneca)

Canada flag
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the U.S. rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

09-Aug-16
$NA
Australia flag
Target: 

Bionomics Limited

flag not available

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

08-Aug-16
$1.5 billion
Canada flag
Target: 

Whistler Blackcomb Holdings Inc.

United States flag
Acquiror: 
Vail Resorts, Inc.

Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.

28-Jul-16
$80 million
United States flag
Target: 

BioD, LLC

United States flag
Acquiror: 
Derma Sciences, Inc.

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.

28-Jun-16
$NA
Israel flag
Target: 

U.S. rights to an authorized generic version of Adderall XR

United States flag
Acquiror: 
Prasco Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights  to an authorized generic version of Adderall XR

28-Jun-16
$652 million
Israel flag
Target: 

U.S. rights to 37 approved and 5 pipeline generic products

Australia flag
Acquiror: 
Mayne Pharma Group Limited

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights  to 42 generic products

21-Jun-16
$586 million
Israel flag
Target: 

U.S. rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Impax Laboratories, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

Pages

show all